As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.
14 Analysts have issued a Erasca Inc forecast:
14 Analysts have issued a Erasca Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -136 -136 |
6%
6%
|
|
| EBIT (Operating Income) EBIT | -139 -139 |
6%
6%
|
|
| Net Profit | -128 -128 |
19%
19%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Jonathan Lim |
| Employees | 103 |
| Founded | 2018 |
| Website | www.erasca.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


